CA2777473C - Compounds and methods for the treatment of cancer - Google Patents

Compounds and methods for the treatment of cancer Download PDF

Info

Publication number
CA2777473C
CA2777473C CA2777473A CA2777473A CA2777473C CA 2777473 C CA2777473 C CA 2777473C CA 2777473 A CA2777473 A CA 2777473A CA 2777473 A CA2777473 A CA 2777473A CA 2777473 C CA2777473 C CA 2777473C
Authority
CA
Canada
Prior art keywords
cancer
compound
cells
10alkyl
leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2777473A
Other languages
English (en)
French (fr)
Other versions
CA2777473A1 (en
Inventor
Ralph A. Zingaro
Hatice Duzkale
Emil J. Freireich
Hagop Kantarjian
Merida Sotelo-Lerma
Srdan Verstovsek
Mingzhang Gao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Texas A&M University System
University of Texas System
Original Assignee
Texas A&M University System
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas A&M University System, University of Texas System filed Critical Texas A&M University System
Publication of CA2777473A1 publication Critical patent/CA2777473A1/en
Application granted granted Critical
Publication of CA2777473C publication Critical patent/CA2777473C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/66—Arsenic compounds
    • C07F9/70—Organo-arsenic compounds
    • C07F9/72—Aliphatic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/66—Arsenic compounds
    • C07F9/70—Organo-arsenic compounds
    • C07F9/74—Aromatic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/66—Arsenic compounds
    • C07F9/70—Organo-arsenic compounds
    • C07F9/80—Heterocyclic compounds
    • C07F9/82—Arsenic compounds containing one or more pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2777473A 2004-07-16 2005-07-15 Compounds and methods for the treatment of cancer Expired - Fee Related CA2777473C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58859604P 2004-07-16 2004-07-16
US60/588,596 2004-07-16
CA2574032A CA2574032C (en) 2004-07-16 2005-07-15 Compounds and methods for the treatment of cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2574032A Division CA2574032C (en) 2004-07-16 2005-07-15 Compounds and methods for the treatment of cancer

Publications (2)

Publication Number Publication Date
CA2777473A1 CA2777473A1 (en) 2006-02-23
CA2777473C true CA2777473C (en) 2013-08-27

Family

ID=35414967

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2777473A Expired - Fee Related CA2777473C (en) 2004-07-16 2005-07-15 Compounds and methods for the treatment of cancer
CA2574032A Expired - Fee Related CA2574032C (en) 2004-07-16 2005-07-15 Compounds and methods for the treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2574032A Expired - Fee Related CA2574032C (en) 2004-07-16 2005-07-15 Compounds and methods for the treatment of cancer

Country Status (11)

Country Link
US (2) US7405314B2 (https=)
EP (1) EP1771459A2 (https=)
JP (3) JP5618461B2 (https=)
KR (5) KR20140013110A (https=)
CN (3) CN104163833A (https=)
AU (1) AU2005274926B2 (https=)
CA (2) CA2777473C (https=)
HK (1) HK1204476A1 (https=)
IL (2) IL180729A (https=)
TW (3) TWI411431B (https=)
WO (1) WO2006020048A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911471B2 (en) 2002-01-07 2005-06-28 The Texas A&M University System S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
US7628810B2 (en) 2003-05-28 2009-12-08 Acufocus, Inc. Mask configured to maintain nutrient transport without producing visible diffraction patterns
TWI411431B (zh) * 2004-07-16 2013-10-11 Texas A & M Univ Sys 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物
ES2532666T3 (es) 2005-07-29 2015-03-30 Solasia Pharma K.K. Compuestos y métodos para el tratamiento del cáncer
WO2007082104A2 (en) 2006-01-13 2007-07-19 The Texas A & M University System Compounds and methods for the treatment of cancer
RU2318519C2 (ru) * 2006-03-06 2008-03-10 ФГУ Ростовский научно-исследовательский онкологический институт Росздрава Способ химиотерапии острого лейкоза
TW200829261A (en) 2006-09-29 2008-07-16 Ziopharm Oncology Inc Method for controlling angiogenesis in animals
KR20100100835A (ko) * 2007-11-02 2010-09-15 지오팜 온콜로지 인코포레이티드 유기 비소제와의 병용 요법
SG186599A1 (en) * 2007-12-12 2013-01-30 Ziopharm Oncology Inc Compounds and methods for the treatment of cancer
RU2534606C2 (ru) * 2008-08-20 2014-11-27 Зайофарм Онколоджи, Инк. Мышьякорганические соединения и способы лечения рака
CN102060722B (zh) * 2009-05-01 2014-06-11 常州高新技术产业开发区三维工业技术研究所有限公司 一种含砷化合物及其制备方法和用途
US10004593B2 (en) 2009-08-13 2018-06-26 Acufocus, Inc. Intraocular lens with elastic mask
US9492272B2 (en) 2009-08-13 2016-11-15 Acufocus, Inc. Masked intraocular implants and lenses
JP2014516075A (ja) 2011-06-06 2014-07-07 シェブロン フィリップス ケミカル カンパニー エルピー 癌治療のためのメタロセン化合物の使用
EP2785296B1 (en) 2011-12-02 2018-06-20 AcuFocus, Inc. Ocular mask having selective spectral transmission
US9427922B2 (en) 2013-03-14 2016-08-30 Acufocus, Inc. Process for manufacturing an intraocular lens with an embedded mask
TWI617305B (zh) * 2013-12-05 2018-03-11 蘇愛康制藥有限公司 治療癌症的化合物及其應用程序
GB201418491D0 (en) * 2014-10-17 2014-12-03 Monfort University De Compounds
EP3220859B8 (en) 2014-11-19 2020-06-10 AcuFocus, Inc. Fracturable mask for treating presbyopia
US10687935B2 (en) 2015-10-05 2020-06-23 Acufocus, Inc. Methods of molding intraocular lenses
JP7055747B2 (ja) 2015-11-24 2022-04-18 アキュフォーカス・インコーポレーテッド 焦点深度の拡張を伴うトーリック小開口眼内レンズ
CN105330701B (zh) * 2015-11-27 2017-05-31 昆明医科大学 一种含砷化合物及其制备方法和应用
EP3790508B1 (en) 2018-05-09 2026-04-29 AcuFocus, Inc. Intraocular implant with optic

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001519366A (ja) * 1997-10-15 2001-10-23 ポーラクス バイオファーマシュティカルズ，インコーポレーテッド ヒ素化合物を用いた、原発性および転移性の腫瘍性疾患を治療するための組成物および方法
IL136051A0 (en) * 1997-11-10 2001-05-20 Sloan Kettering Inst Cancer Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
CN1233476A (zh) * 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
EP1002537A1 (en) 1998-10-30 2000-05-24 Assistance Publique, Hopitaux De Paris Use of melarsoprol for the manufacture of a medicament for treating B-cell lymphoproliferative diseases, such as multiple myeloma
US6191123B1 (en) * 1999-03-19 2001-02-20 Parker Hughes Institute Organic-arsenic compounds
EP1328253B1 (en) * 2000-04-26 2006-03-22 Oregon Health Sciences University Administration of a thiol-based chemoprotectant compound
US6911471B2 (en) * 2002-01-07 2005-06-28 The Texas A&M University System S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
TWI411431B (zh) * 2004-07-16 2013-10-11 Texas A & M Univ Sys 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物

Also Published As

Publication number Publication date
IL180729A0 (en) 2007-06-03
KR20140136525A (ko) 2014-11-28
CN104163833A (zh) 2014-11-26
CN101076533A (zh) 2007-11-21
JP5618461B2 (ja) 2014-11-05
JP2014122233A (ja) 2014-07-03
EP1771459A2 (en) 2007-04-11
CA2574032A1 (en) 2006-02-23
IL215896A0 (en) 2011-12-29
WO2006020048A3 (en) 2006-08-24
KR101252866B1 (ko) 2013-04-10
US7405314B2 (en) 2008-07-29
KR20130095857A (ko) 2013-08-28
KR20140013110A (ko) 2014-02-04
KR20070046120A (ko) 2007-05-02
TW201440760A (zh) 2014-11-01
HK1204476A1 (en) 2015-11-20
US20080090793A1 (en) 2008-04-17
WO2006020048B1 (en) 2006-10-19
TW200616615A (en) 2006-06-01
CN101076533B (zh) 2013-11-06
JP2012051919A (ja) 2012-03-15
JP2008506710A (ja) 2008-03-06
JP5745660B2 (ja) 2015-07-08
CA2777473A1 (en) 2006-02-23
WO2006020048A2 (en) 2006-02-23
KR20130001323A (ko) 2013-01-03
US20060128682A1 (en) 2006-06-15
TW201350113A (zh) 2013-12-16
AU2005274926B2 (en) 2011-04-28
CA2574032C (en) 2015-02-24
IL180729A (en) 2012-03-29
AU2005274926A1 (en) 2006-02-23
TWI411431B (zh) 2013-10-11
CN105777811A (zh) 2016-07-20

Similar Documents

Publication Publication Date Title
CA2777473C (en) Compounds and methods for the treatment of cancer
US11324713B2 (en) Organoarsenic compounds and methods for the treatment of cancer
EP1474128B1 (en) S-dimethylarsino-thiosuccinic acid, s-dimethylarsino-2-thiobenzoic acid, s-(dimethylarsino)glutathione as treatments for cancer
AU2011204901B2 (en) Compounds and methods for treatment of cancer
AU2007249110C1 (en) S-dimethylarsino-thiosuccinic acid S-dimethylarsino-2-thiobenzoic acid S-(dimethylarsino) glutathione as treatment for cancer
HK1166959A (en) S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
HK1171952A (en) S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160715